Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

WB-EMS and Diet Effects on Body Composition, Cardiometabolic Markers, and Myokines in Obese Women

26. Juni 2026 aktualisiert von: Murat Açık, Firat University

Effects of an Eight-Week Whole-Body Electromyostimulation and Diet Program on Body Composition, Cardiometabolic Markers, and the Myokines Irisin and Betatrophin in Women With Obesity: A Randomized Controlled Trial

This randomized controlled trial investigated the effects of an 8-week whole-body electromyostimulation (WB-EMS) combined with a hypocaloric diet on body composition, cardiometabolic markers, and serum levels of the myokines irisin and betatrophin (ANGPTL8) in women with obesity. Participants were randomly assigned to either a diet-only group or a diet plus WB-EMS group. WB-EMS sessions were conducted twice weekly (20-25 minutes per session) over 8 weeks. The primary outcomes included BMI, body fat percentage, lean body mass, fasting blood glucose, insulin, HOMA-IR, HbA1c, lipid profile, CRP, and serum irisin and betatrophin concentrations. The study aimed to evaluate whether WB-EMS adds metabolic and myokine-related benefits beyond those achieved by dietary restriction alone in obese women.

Studienübersicht

Status

Abgeschlossen

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This study was a randomized controlled trial (RCT) designed to investigate the effects of an 8-week whole-body electromyostimulation (WB-EMS) combined with a hypocaloric diet on body composition, cardiometabolic markers, and serum levels of the myokines irisin and betatrophin (ANGPTL8) in women with obesity.

Participants were randomly assigned to one of two groups: (1) Diet-only group (control): received a hypocaloric diet prescription without exercise training; (2) WB-EMS + Diet group (intervention): received the same hypocaloric diet plus WB-EMS training sessions conducted twice weekly (20-25 minutes per session) over 8 weeks.

Body composition assessments included body weight, BMI, body fat percentage, fat mass, fat-free mass, and waist circumference, measured using multifrequency bioelectrical impedance analysis (InBody 270). Cardiometabolic markers assessed included fasting blood glucose, serum insulin, HOMA-IR, HbA1c, total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, blood pressure, and C-reactive protein (CRP). Serum irisin and betatrophin concentrations were measured at baseline and post-intervention using ELISA.

The primary aim was to evaluate whether WB-EMS combined with dietary restriction provides additional metabolic and myokine-related benefits beyond those achieved by dietary restriction alone in obese women.

Studientyp

Interventionell

Einschreibung (Tatsächlich)

44

Phase

  • Unzutreffend

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienorte

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Beschreibung

Inclusion Criteria:

  • Adult women aged 18-65 years
  • BMI >= 30 kg/m2 (obesity)
  • Sedentary lifestyle (no regular physical activity for the past 6 months)
  • Willingness to participate and provide written informed consent

Exclusion Criteria:

  • Pregnancy or breastfeeding
  • Cardiovascular disease, neurological disorders, or implanted pacemaker/defibrillator
  • Active cancer or ongoing chemotherapy/radiotherapy
  • Use of medications affecting body weight or metabolic parameters
  • Prior WB-EMS training experience
  • Skin conditions contraindicating electrode use

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

  • Hauptzweck: Behandlung
  • Zuteilung: Zufällig
  • Interventionsmodell: Parallele Zuordnung
  • Maskierung: Keine (Offenes Etikett)

Waffen und Interventionen

Teilnehmergruppe / Arm
Intervention / Behandlung
Aktiver Komparator: Diet Only
Participants received an 8-week individualized hypocaloric diet program only. The diet was prescribed based on the Mifflin-St. Jeor equation with a 500 kcal/day deficit.
Verhalten: Hypocaloric Diet
An individualized hypocaloric diet with a 500 kcal/day deficit calculated using the Mifflin-St. Jeor equation, prescribed to both study arms for 8 weeks.
Experimental: Diet + WB-EMS
Participants received an 8-week individualized hypocaloric diet program combined with whole-body electromyostimulation (WB-EMS) training. The diet was prescribed based on the Mifflin-St. Jeor equation with a 500 kcal/day deficit. WB-EMS sessions were performed twice per week for 20 minutes using a full-body electrostimulation suit.
Verhalten: Hypocaloric Diet
An individualized hypocaloric diet with a 500 kcal/day deficit calculated using the Mifflin-St. Jeor equation, prescribed to both study arms for 8 weeks.
Gerät: Whole-Body Electromyostimulation (WB-EMS)
WB-EMS training was performed twice per week for 8 weeks, with 20-minute sessions using a full-body electrostimulation suit. Stimulation parameters: frequency 85 Hz, pulse width 350 µs, intermittent mode (4 s on / 4 s off), with simultaneous dynamic exercises.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Body Weight
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in body weight (kg) measured by multifrequency bioelectrical impedance analyser (InBody 270) from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Body Mass Index (BMI)
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in body mass index (BMI, kg/m²) measured by multifrequency bioelectrical impedance analyser (InBody 270) from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Body Fat Percentage
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in body fat percentage (%) measured by multifrequency bioelectrical impedance analyser (InBody 270) from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Fat Mass
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in fat mass (kg) measured by multifrequency bioelectrical impedance analyser (InBody 270) from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Fat-Free Mass (Lean Body Mass)
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in fat-free mass / lean body mass (kg) measured by multifrequency bioelectrical impedance analyser (InBody 270) from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Waist Circumference
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in waist circumference (cm) measured by standard anthropometric tape from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)

Sekundäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
Fasting Blood Glucose (FBG)
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in fasting blood glucose (mg/dL) measured by standard automated clinical chemistry platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Serum Insulin
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in serum insulin (µIU/mL) measured by immunoassay platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
HOMA-IR (Insulin Resistance)
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in HOMA-IR (calculated as fasting insulin x fasting glucose / 405) from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Glycated Haemoglobin (HbA1c)
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in HbA1c (%) measured by immunoassay platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Total Cholesterol (TC)
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in total cholesterol (mg/dL) measured by standard automated clinical chemistry platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Triglycerides (TG)
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in serum triglycerides (mg/dL) measured by standard automated clinical chemistry platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
LDL Cholesterol (LDL-C)
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in LDL cholesterol (mg/dL) measured by standard automated clinical chemistry platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
HDL Cholesterol (HDL-C)
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in HDL cholesterol (mg/dL) measured by standard automated clinical chemistry platform from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
C-Reactive Protein (CRP)
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in serum C-reactive protein (mg/L) measured by high-sensitivity immunoassay from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Serum Irisin
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in serum irisin levels (ng/mL) measured by ELISA from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Serum Betatrophin (ANGPTL8)
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in serum betatrophin (ANGPTL8) levels (ng/mL) measured by ELISA from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Systolic Blood Pressure
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in systolic blood pressure (mmHg) measured by sphygmomanometer after 10 minutes of rest from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)
Diastolic Blood Pressure
Zeitfenster: 8 weeks (baseline to post-intervention)
Changes in diastolic blood pressure (mmHg) measured by sphygmomanometer after 10 minutes of rest from baseline to post-intervention (8 weeks).
8 weeks (baseline to post-intervention)

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Firat University

Mitarbeiter

Dicle University

Ermittler

  • Studienleiter: Fazilet Erman, Dr, Firat University
  • Studienleiter: Feray Cagiran Yilmaz, Dr, Dicle University
  • Studienleiter: Esra Das, Msc, Firat University

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Tatsächlich)

1. Mai 2025

Primärer Abschluss (Tatsächlich)

1. März 2026

Studienabschluss (Tatsächlich)

1. März 2026

Studienanmeldedaten

Zuerst eingereicht

17. Juni 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

26. Juni 2026

Zuerst gepostet (Tatsächlich)

30. Juni 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

30. Juni 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

26. Juni 2026

Zuletzt verifiziert

1. Juni 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • FU_MAcik_WB-EMS_2025
  • 30456 (Andere Kennung: Firat Univ. Non-Interventional Research Ethics Comm.)

Plan für individuelle Teilnehmerdaten (IPD)

Planen Sie, individuelle Teilnehmerdaten (IPD) zu teilen?

NEIN

Beschreibung des IPD-Plans

Individual participant data will not be publicly shared due to institutional privacy policies.

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Abonnieren